A combined Russian and German research team has provided some interesting preliminary information on the use of neoadjuvant, low-dose docetaxel-based chemotherapy in treatment of intermediate- and high-risk patients prior to radical prostatectomy. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: "high risk", chemotherapy, intermediate risk, localized, prostatectomy, radical | Leave a comment »
The question of whether PSA kinetics (e.g., PSA doubling time and PSA velocity) can be used to accurately project risk for prostate cancer progression and mortality is still not definitively known (although it is much debated). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: kinetics, localized, prognosis, PSA | 14 Comments »
A report in the Journal of Radiation Oncology is making big claims for the effectiveness of a combination of intensity-modulated radiation therapy (IMRT) along with “suicide gene” therapy as first-line treatment for localized prostate cancer … but there are some real questions that need real answers. … READ MORE …
Filed under: Diagnosis, Drugs in development, Management, Risk, Treatment | Tagged: ADV/HSV-tk, gene, localized, suicide | 2 Comments »
From the perspective of the disinterested observer, one of the very least edifying aspects of issues related to the management of prostate cancer has been the nearly 50-year-long “discussion” between the urology community and the radiation oncology community about the most appropriate way(s) to treat localized disease. … READ MORE …
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: "best", high, intermediate, localized, registry, risk, Treatment, trial | 11 Comments »
A recent article in the journal BMC Cancer has suggested a strong association between neutrophil count and risk for overall mortality among a cohort of Canadian men treated for prostate cancer with radiation therapy ± androgen deprivation therapy (ADT). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: count, localized, neutrophil, radiation, risk, survival, therapy | 8 Comments »
The potential to use some form of second-line radiation therapy after failure of first-line radiation therapy has long been intriguing, and is highly dependent on the dose and precise volume of the target of first-line radiation therapy. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: brachytherapy, localized, persistent, radiation, repeat, slavage | 1 Comment »
As regular readers will be aware, Nymox Pharmaceutical has been developing a drug called NX-1207 for the treatment of benign prostatic hypertrophy (BPH) and for the treatment of localized prostate cancer. … READ MORE …
Filed under: Diagnosis, Drugs in development, Management, Treatment | Tagged: localized, NX-1207, Nymox | 1 Comment »
Back in September 2011, a company called Advantagene initiated a randomized, placebo-controlled, Phase III clinical trial (the PrKT01 trial) of an immunotherapeutic agent known as AdV-tk, together with with standard external beam radiation therapy, in highly-defined patients with newly diagnosed, localized prostate cancer. … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: AdV-tk, immunotherapy, localized, radiation, trial | 1 Comment »
For men who choose to have radiotherapy (external photon beam, external proton beam, or brachytherapy of some type) as first-line therapy for localized prostate cancer, a major issue is, “What if the cancer recurs after treatment?” … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: localized, progression, radiorecurrent, Treatment | 6 Comments »
A case study report in the journal Research and Reports in Urology (which is not exactly a widely read publication) addresses the treatment of an elderly man with low-risk prostate cancer with low-dose enzalutamide as a form of first-line therapy. … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: enzalutamide, intermediate risk, localized | 3 Comments »
The appropriate use of focal therapy in the treatment of low-risk and perhaps intermediate-risk prostate cancer is a very controversial topic (despite the heavy promotion of this type of treatment by a relatively small number of clinicians). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment, Uncategorized | Tagged: focal, localized | 55 Comments »
Another interesting presentation being made at the ASCO annual meeting this year will be the first report on a series of nearly 400 patients who did not conform to what would normally be considered a series of sound criteria for low risk disease. These patients all elected, as individuals, to go on actiuve surveillance despite their higher than average risk for progression. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active, expectant, localized, Management, risk, surveillance | Leave a comment »
The Nymox Pharmaceutical Corp. seems to have decided to issue data from the Phase III clinical trial of NX-1207 in a series of media releases over time (which is a more than slightly odd way of going about such things). … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: localized, low risk, NX-1207 | 2 Comments »
According to a media release issued yesterday by the City of Hope medical center in Los Angeles, they have become the first center in the USA to treat a patient with focused, MRI-guided, ultrasound technology using the InSightec system. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: focal, InSightec, localized, low risk, MRi-guided, Treatment, ultrasound | 3 Comments »
For those who are interested in the current state of focal therapy in the management of localized, organ-confined prostate cancer, there is a nice audio overview by Dr. James Eastham of the Memorial Sloan-Kettering Cancer Center on the UroToday web site. … READ MORE …
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: focal, localized, organ-confined | 6 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 